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Abstract
Non-Hodgkin lymphoma (NHL) represents a diverse group of hematological malignancies, of which follicular lymphoma (FL)
is a prevalent subtype. A previous genome-wide association study has established a marker, rs10484561 in the human
leukocyte antigen (HLA) class II region on 6p21.32 associated with increased FL risk. Here, in a three-stage genome-wide
association study, starting with a genome-wide scan of 379 FL cases and 791 controls followed by validation in 1,049 cases
and 5,790 controls, we identified a second independent FL–associated locus on 6p21.32, rs2647012 (ORcombined=0.64,
Pcombined=2 610
221) located 962 bp away from rs10484561 (r
2,0.1 in controls). After mutual adjustment, the associations
at the two SNPs remained genome-wide significant (rs2647012:ORadjusted=0.70, Padjusted=4 610
212; rs10484561:OR-
adjusted=1.64, Padjusted=5 610
215). Haplotype and coalescence analyses indicated that rs2647012 arose on an evolutionarily
distinct haplotype from that of rs10484561 and tags a novel allele with an opposite (protective) effect on FL risk. Moreover,
in a follow-up analysis of the top 6 FL–associated SNPs in 4,449 cases of other NHL subtypes, rs10484561 was associated
with risk of diffuse large B-cell lymphoma (ORcombined=1.36, Pcombined=1.4610
27). Our results reveal the presence of allelic
heterogeneity within the HLA class II region influencing FL susceptibility and indicate a possible shared genetic etiology
with diffuse large B-cell lymphoma. These findings suggest that the HLA class II region plays a complex yet important role in
NHL.
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Introduction
Non-Hodgkin lymphoma (NHL) represents a diverse group of
B- and T-cell malignancies of lymphatic origin. The most common
subtypes are of B-cell origin and are further classified on the basis
of their resemblance to normal stages of B-cell differentiation [1].
Epidemiological studies indicate that these may have different
environmental and genetic risk factors, although some etiological
factors may also be shared [2]. Familial studies provide substantial
evidence for a genetic influence on susceptibility to the major
mature B-cell neoplasms, including diffuse large B-cell lymphoma
(DLBCL), follicular lymphoma (FL) and chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL) [3,4]. Recent
genome-wide association studies (GWAS) of the FL subtype of
NHL identified associations with two variants within the human
leukocyte antigen (HLA) region, one at 6p21.33 (rs6457327) [5]
and the other at 6p21.32 (rs10484561) [6]. Additional true
associations, particularly in the HLA region, may have been
missed because a limited number of samples were used in the
initial genome-wide screens, and the selection of a few top single
nucleotide polymorphisms (SNPs) for validation is further subject
to chance. In this study, we conducted a larger independent
genome-wide scan of FL using 379 cases and 791 controls from the
Scandinavian Lymphoma Etiology (SCALE) study of Sweden and
Denmark, which was used in the validation of the previous GWAS
[6]. This scan was followed by two stages of validation in
European-ancestry cases of FL and other common B-cell NHL
subtypes and controls from the US, Canada and Australia (Table 1,
Table S1, Table S2, Figure 1).
Results
In total, 298,168 SNPs were analyzed in Stage 1 (l=1.028;
l1000=1.055 [7]), in which we observed suggestive associations
(adjusted trend P-value,10
25) at 4q32.3, 6p21.32 and 10q25.3
(Table S3) with the strongest at rs2647012 (odds ratio (OR)=0.58,
PPCAadjusted= 1.59x10
27) within the HLA class II region on
6p21.32. Sixteen SNPs in close proximity to the HLA-DQ genes
showed association with adjusted P-values,10
24, including the
previously reported rs10484561 (Figure 2, Table S4) [6]. The
previously reported HLA class I associated SNP rs6457327 [5] was
modestly associated with FL risk (OR=0.82, P=0.03) in Stage 1,
and was not in linkage disequilibrium (LD; r
2=0) with any of the
top 100 SNPs.
In Stage 2, we carried out an in silico validation of the top 40
SNPs from Stage 1 (Table S5) in 213 FL cases and 750 controls
from the San Francisco Bay Area, USA (Table 1), the study that
reported an association at 6p21.32 [6]. Among 38 out of 40 SNPs,
seven showed association (P,0.05) in Stage 2 (Table S5), six of
which were located within the 6p21.32 region. We tested the
independence of multiple association signals in 6p21.32 using a
stepwise logistic regression analysis (entering SNPs based on a
criterion of likelihood ratio test p-value,0.05) and found that with
rs2647012 (the top SNP within the region) forced in the model,
only the addition of rs10484561 contributed significantly to the
association with increased risk of FL. The OR for this SNP,
adjusted for rs2647012, was 1.43, P=0.006 (Table S6).
After excluding previously identified and non-independent
association signals, we selected rs2647012, and an additional four
top SNPs to be taken forward to a third stage (Table S7, S8),
wherein these were genotyped in 836 FL cases and 3202 controls
from the Mayo Clinic (US) [8], National Cancer Institute-
Surveillance, Epidemiology and End Results (NCI-SEER, US)
[9], Yale University (US) [10], New South Wales (NSW, Australia)
[11] and British Columbia (BC, Canada) [12] studies. The
association of rs2647012 with FL was validated, showing consistent
associations with similar ORs (no heterogeneity, P=0.32) across all
independent studies and reaching genome-wide significance in both
the combined analysis of the validation samples (P=3610
215)a n d
the combined analysis of all three stages (1428 FL cases, 4743
controls; OR=0.64, P=2610
221) (Table.2, Figure 3). After
adjustment for rs10484561, the association at rs2647012 remained
genome-wide significant with minimal change in magnitude
(ORadjusted=0.70, Padjusted=4 610
212). The LD between the two
SNPs is low (r
2,0.1 in the SCALE controls and HapMap CEU
[Utah residents with northern and western European ancestry]
samples release27). Taken together, our results suggest that the
association at rs2647012 is independent from rs10484561, and tags
a different disease-predisposing variant. We also found suggestive
evidence for an association at rs6536942 on 4q32.3 (OR=1.36,
P=2 610
25) (Table 2, Figure S1A).
To fine-map the association signals in the HLA class II region,
we imputed 10,639 SNPs within 600 kb surrounding the top SNP
rs2647012 using data from the 1000 Genomes (1000G, 60 CEU
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      subjects, August 2009) and HapMap projects (HapMapII release
22, CEU) in Stage 1. Among the imputed SNPs, 258 SNPs located
in a strong LD block of 236 kb (r
2.0.8) showed stronger evidence
of association than all the genotyped SNPs within the region
(Figure S2). Since a moderate discordance of reference genotypes
was observed between 1000 G and HapMapII, we analyzed only
SNPs showing a concordance of .95% in the two datasets and
identified the strongest association at rs9378212 (OR=1.66,
P=3.21610
28), located 219 kb upstream of rs2647012 (r
2=0.56
in controls). We subsequently confirmed the imputed genotypes by
Taqman genotyping in 345 of the FL case subjects used in Stage 1
and found a 99.4% concordance with the imputed genotypes,
demonstrating high confidence in the results of the imputation.
Next, we performed a haplotype analysis using rs2647012,
rs10484561 and an additional 12 adjacent genotyped SNPs
located within a block of minimal recombination. Out of the eight
haplotypes identified, three were neutral (OR=0.9–1.1), three
increased risk (ORs.1.2; strongest risk haplotype tagged by
rs10484561) and two were protective (OR#0.8; both tagged by
rs2647012) (Table S9), suggesting the presence of at least two
susceptibility alleles within the region. Coalescence analysis of the
eight haplotypes indicated that rs2647012 and rs10484561 arose
on two distal branches of the ancestral recombination graph [13]
(Figure S3), which was also supported by the analysis of median-
joining network [14] using seven SNPs without any recombination
(Figure 4). Further haplotype analysis of the seven genotyped SNPs
(Table S9) and the imputed SNP rs9378212 indicated that the two
alleles of rs9378212 tag the two different evolutionary lineages
(Figure 4), each harboring either rs2647012 or rs10484561. Thus,
the associations at the two SNPs are likely due to two distinct
susceptibility variants, instead of a single risk allele, that arose
independently on different haplotype backgrounds.
The FL-associated SNP, rs10484561, was previously found to
tag the extended haplotype HLA-DQA1*0101-HLA-DQB1*0501-
HLA-DRB1*0101 [6]. Here, to test whether any HLA class II
alleles may also be responsible for the observed association at
rs2647012, we imputed known HLA tag SNPs [15,16] using data
from the 1000G and HapMapII European datasets. We confirmed
the association of the HLA-DRB1*0101-HLA-DQA1*0101-HLA-
DQB1*0501 extended haplotype, tagged by rs10484561. The
association at rs2647012 remained significant after adjustment for
these three HLA alleles (OR=0.64, P=8.11610
26), suggesting
that these are not driving the association at rs2647012.
Furthermore, rs2647012 was not in strong LD (r
2,0.8 in
HapMap CEU or SCALE controls) with any other known HLA
tags [15], including those tagging FL-associated alleles previously
reported [17,18] (r
2,0.39 with the six HLA-DRB1*13 tag SNPs
[rs2395173, rs2157051, rs4434496, rs6901541, rs424232,
rs2050191] [17] and r
2,0.25 with the three HLA-B*0801 and
HLA-DRB*0301 tag SNPs [rs6457374, rs2844535, rs2040410]
[15]). Of the other 17 HLA class II alleles (,39% of all the class II
alleles) that could be imputed, none showed significant association
or were found to be responsible for the association at rs2647012
(Table S10). Detailed HLA allelotyping on large numbers of cases
and controls is needed to determine if particular HLA class II
alleles are responsible for the observed association at rs2647012.
To assess whether the FL-associated SNPs may be involved in
the development of other NHL subtypes, we genotyped the five
SNPs selected for Stage 3 together with rs10484561 in a total of
1592 DLBCL, 1075 CLL/SLL, 336 marginal zone lymphoma
(MZL), 262 mantle cell lymphoma, 306 T-cell lymphoma and 878
rare or unspecified NHL cases and 5220 controls from the
SCALE2, SF2, BC, Mayo, NCI-SEER, Yale and NSW studies
Author Summary
Earlier studies have established a marker rs10484561, in
the HLA class II region on 6p21.32, associated with
increased follicular lymphoma (FL) risk. Here, in a three-
stage genome-wide association study of 1,428 FL cases
and 6,581 controls, we identified a second independent
FL–associated marker on 6p21.32, rs2647012, located 962
bp away from rs10484561. The associations at two SNPs
remained genome-wide significant after mutual adjust-
ment. Haplotype and coalescence analyses indicated that
rs2647012 arose on an evolutionarily distinct lineage from
that of rs10484561 and tags a novel allele with an
opposite, protective effect on FL risk. Moreover, in an
analysis of the top 6 FL–associated SNPs in 4,449 cases of
other NHL subtypes, rs10484561 was associated with risk
of diffuse large B-cell lymphoma. Our results reveal the
presence of allelic heterogeneity at 6p21.32 in FL risk and
suggest a shared genetic etiology with the common
diffuse large B-cell lymphoma subtype.
Table 1. Summary of contributing studies, genotyping methods, and number of samples per case/control status.
Stage Study Population Genotyping method Controls FL Other NHL subtypes*
1 SCALE1 Denmark/Sweden Illumina 317k 791 379 -
2 SF1 San Francisco Bay Area, USA Illumina HumanCNV370-Duo Beadchip 750 213 -
3/subtype
validation
NCI-SEER USA Taqman 501 157 468
NSW New South Wales, Australia Taqman 398 161 261
Yale USA Taqman 460 98 300
BC British Columbia, Canada Taqman 610 174 451
Mayo Minnesota, Iowa, Wisconsin, USA OPA 1233 246 843
SCALE2 Denmark/Sweden Sequenom/Taqman 2018 - 1869
SF2 San Francisco Bay Area, USA Illumina HumanCNV370-Duo Beadchip - - 257
Total 6761 1428 4449
Abbreviations: SCALE: Scandinavian lymphoma etiology, SF: San Francisco, NCI-SEER: National Cancer Institute- Surveillance, Epidemiology and End Results, NSW: New
South Wales, Yale: Yale University, BC: British Columbia, Mayo: Mayo Clinic, OPA: oligonucleotuide pool assays (Illumina GoldenGate).
*The complete list of the number of other NHL subtypes in each study is detailed in Table S1.
doi:10.1371/journal.pgen.1001378.t001
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showed evidence of association with DLBCL (OR=1.36,
P=1.41610
27) (Figure S1B) and all NHL (OR=1.23,
P=6.81610
27). ORs were consistent across the seven studies.
There was also a suggestive association for rs2647012 with MZL
(OR=1.32, P=6.34610
24) (Table.3), consistent across six
studies.
Finally, we investigated the possibility of additional susceptibility
loci for FL outside of the HLA region by performing a joint
analysis of the top 41 to 1000 variants of our scan and the
previously published GWAS of follicular lymphoma [6]. From this
combined analysis, we did not find any additional markers with a
strong association (P,10
26) with FL that were not in LD with our
top 5 markers taken forward to stage 3 (data not shown).
Figure 1. Schematic representation of the three-stage study design. Summary of contributing studies and number of samples per case/
control status. Abbreviations: FL: follicular lymphoma, NHL: non-Hodgkin lymphoma, DLBCL: diffuse large B-cell lymphoma, CLL/SLL: chronic
lymphocytic leukemia/small lymphocytic lymphoma, SNP: single nucleotide polymorphism, GWAS: genome-wide association study, SCALE:
Scandinavian lymphoma etiology, SF: San Francisco, BC: British Columbia, NCI-SEER: National Cancer Institute-Surveillance, Epidemiology and End
Results, NSW: New South Wales, Yale: Yale University, Mayo: Mayo Clinic. The complete list of the number of other NHL subtypes in each study is
detailed in Table S1.
doi:10.1371/journal.pgen.1001378.g001
Figure 2. Recombination plot showing associations in 6p21.32 in Stage 1. Plot showing the pattern of associations in Stage 1, the
recombination rate (build 36, HapMap CEU) and genes located in the region. The two SNPs showing independent association and their respective
P-values are labeled (blue: rs2647012, green: rs10484561); other SNPs are color-coded according to their LD with rs2647012 (red r
2.0.8, orange
0.5–0.8, grey 0.2–0.5, white ,0.2).
doi:10.1371/journal.pgen.1001378.g002
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Through the identification of a second variant, rs2647012, that
is independent of the previously identified risk variant rs10484561
[6] within the 6p21.32 region, our findings substantiate a major
link between HLA class II loci and genetic susceptibility to FL. In
addition, our study revealed evidence that rs10484561 is
associated with DLBCL risk suggesting some shared biological
mechanisms of susceptibility between these two common NHL
subtypes. The association of rs2647012 with FL risk was not
detected in earlier GWAS studies [5,6], and that of rs10484561
with DLBCL risk previously reported was only marginal [6],
perhaps because of the smaller sample sizes in Stage 1. The
number of FL cases scanned in this study was almost double
compared to the previous individual GWAS [6].
HLA class II molecules are expressed in antigen presenting cells
such as B-lymphocytes, and act to present exogenous antigens
to CD4+ helper T-cells. Efficiency of antigen presentation may
influence lymphomagenesis through effects on anti-tumor immu-
nity or on immune response to infections that are directly or
indirectly oncogenic (e.g., through viral genome insertion or
nonspecific chronic antigenic stimulation) [19]. Allelic variants in
coding regions may affect the structure of the peptide binding
groove of the class II molecules, leading to differences in the
efficiency of oncogenic peptide binding or T-cell recognition.
Coding sequence variation in the molecules encoded by the
extended HLA-DRB1*0101-HLA-DQA1*0101-HLA-DQB1*0501
haplotype may be responsible for the association at rs10484561
[6].
Alternatively, variants in the regulatory sequences may
influence the expression level of the HLA molecules and
consequently the efficiency of antigen presentation. We note that
rs2647012 is strongly associated with the average expression levels
of HLA-DRB4 (b=0.78, P=3.4610
-22) and HLA-DQA1 (b=-0.58,
P=5.1610
213) probes in Epstein-Barr virus-transfected lympho-
blastoid cell lines (mRNA by SNP browser) [20], and rs10484561
Table 2. Summary of main findings in genome-wide association study (GWAS) and validation stages in risk* of follicular
lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), or marginal zone lymphoma (MZL), per study and combined.
FL DLBCL MZL
rs2647012
rs2647012adj for
rs10484561**
rs10484561adj for
rs2647012** rs6536942 rs10484561 rs2647012
chr6:32772436
HLA-DQB1
chr4:167205644
TLL1
chr6:32773398
HLA-DQB1
chr6:32772436
HLA-DQB1
Stage 1
SCALE1 1610
27 1610
25 0.006 1610
26 --
0.60 (0.50–0.73) 0.65 (0.53–0.79) 1.43 (1.11–1.84) 1.86 (1.45–2.34)
Stage 2
SF 0.005 0.08 0.002 - 0.04 -
0.72 (0.57–0.91) 0.80 (0.62–1.03) 1.60 (1.19–2.16) 1.36 (1.05–1.80)
Stage 3
BC 0.004 0.06 3610
25 0.72 0.001 0.01
0.69 (0.53–0.89) 0.77 (0.58–1.01) 2.06 (1.46–2.90) 1.08 (0.72–1.61) 1.77 (1.26–2.48) 1.56 (1.10–2.22)
NCI-SEER 0.12 0.17 0.08 0.13 0.15 0.06
0.81 (0.61–1.06) 0.81 (0.59–1.10) 1.41 (0.96–2.08) 1.34 (0.92–1.95) 1.32 (0.90–1.94) 1.51 (0.99–2.31)
NSW 1610
24 0.05 0.006 0.42 0.01 0.45
0.53 (0.38–0.73) 0.69 (0.48–1.01) 1.94 (1.21–3.11) 1.21 (0.76–1.91) 1.74 (1.12–2.72) 1.23 (0.72–2.08)
Yale 0.008 0.04 0.14 0.74 0.40 0.73
0.63 (0.45–0.89) 0.69 (0.48–0.99) 1.38 (0.90–2.12) 1.08 (0.67–1.74) 1.18 (0.79–1.77) 1.10 (0.63–1.92)
Mayo 1610
27 1610
24 0.28 0.28 0.01 0.38
0.56 (0.45–0.69) 0.64 (0.51–0.80) 1.17 (1.45–2.53) 1.17 (0.88–1.56) 1.52 (1.11–2.08) 1.18 (0.82–1.69)
SCALE2 - - - - 0.08 0.10
1.19 (0.98–1.44) 1.29 (0.95–1.74)
Joint 3610
215 6610
28 9610
214 0.06 - -
0.65 (0.58–0.72) 0.73 (0.65–0.82) 1.72 (1.49–1.98) 1.18 (1.00–1.40)
All (Stages
1,2,3)
2610
221 4610
212 5610
215 2610
25 1610
27 6610
24
0.64 (0.58–0.70) 0.70 (0.67–0.78) 1.64 (1.45–1.86) 1.36 (1.18–1.56) 1.36 (1.21–1.52) 1.32 (1.13–1.55)
Pheterogeneity{ 0.32 0.67 0.54 0.09 0.28 0.83
*The trend test P-value for each study is shown with the corresponding odds ratios (OR) and confidence interval (CI) below.
**Additional adjustment for rs6457327, rs4947332, rs1794265, rs1800629, rs2517448 did not confer other than marginal changes.
{Test of heterogeneity carried out assuming heterogeneity of effect of the ‘‘other’’ SNP.
SCALE: Scandinavian Lymphoma Etiology; SF: San Francisco; BC: British Columbia; NCI-SEER: National Cancer Institute-Surveillance, Epidemiology and End Results; NSW:
New South Wales.
doi:10.1371/journal.pgen.1001378.t002
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PLoS Genetics | www.plosgenetics.org 6 April 2011 | Volume 7 | Issue 4 | e1001378Figure 3. Forest plots of main associations with risk of FL. Forest plots showing the associations in each study (ORs and P-values) at rs2647012
before adjustment (Pheterogeneity=0.32), and at rs2647012 (Pheterogeneity=0.67) and rs10484561 (Pheterogeneity=0.54) after mutual adjustment. Squares
indicate the odds ratios, with the size proportional to the weight of the study in the meta-analysis. Abbreviations: CI: confidence interval, SCALE:
Scandinavian lymphoma etiology, SF: San Francisco, BC: British Columbia, NCI: National Cancer Institute-Surveillance, Epidemiology and End Results,
NSW: New South Wales, YALE: Yale University, MAYO: Mayo Clinic.
doi:10.1371/journal.pgen.1001378.g003
Allelic Heterogeneity in Follicular Lymphoma GWAS
PLoS Genetics | www.plosgenetics.org 7 April 2011 | Volume 7 | Issue 4 | e1001378is also associated with the expression levels of HLA-DQA1 probes
(b=-0.884, P=1.6610
210). We speculate that this may be an
alternative mechanism underlying the observed associations,
especially at rs2647012.
Interestingly, SNPs within the same LD block harboring
rs2647012 (r
2.0.7 in HapMap CEU) have previously been
associated with rheumatoid arthritis with the same direction of
effect [21]. Since autoimmune disorders such as rheumatoid
Figure 4. Coalescence analysis of rs2647012 and rs10484561. Median-joining network [14] of haplotypes constructed using seven SNPs
(Table S9). Circles represent haplotypes with area proportional to their frequency. SNPs are shown on the links (black lines). SNPs and haplotypes
associated with increased or decreased FL risk are labeled in red or blue, respectively. The percentage of alleles of the imputed SNP rs9378212 (C/T)
phased on each haplotype are shown in bold.
doi:10.1371/journal.pgen.1001378.g004
Table 3. Meta-analysis of associations between rs1048456, the top 5 markers, and non-Hodgkin lymphoma (NHL) subtypes
(including follicular lymphoma [FL], diffuse large B-cell lymphoma [DLBCL], chronic lymphocytic leukemia/small lymphocytic
lymphoma [CLL/SLL], and others) and overall (All NHL).
FL* DLBCL CLL/SLL Marginal zone Mantle cell T-cell All NHL*
Marker P-value P-value P-value P-value P-value P-value P-value
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
rs10484561 1.06610
221 1.41610
27 0.05 0.31 0.54 0.22 6.81610
27
chr6:32773398
HLA-DQB1
1.94 (1.70–2.21) 1.36 (1.21–1.52) 0.85 (0.73–1.00) 0.87 (0.66–1.14) 0.91 (0.68–1.22) 0.84 (0.64–1.12) 1.23 (1.13–1.34)
rs2647012 6.53610
216 0.36 0.12 6.34610
24 0.15 0.04 0.02
chr6:32772436
HLA-DQB1
0.65 (0.58–0.72) 0.96 (0.88–1.05) 0.92 (0.84–1.02) 1.32 (1.13–1.55) 1.14 (0.95–1.36) 1.20 (1.01–1.41) 0.94 (0.89–0.99)
rs6536942 0.06 0.22 0.53 0.28 0.51 0.56 0.07
chr4:167205644
TLL1
1.18 (1.00–1.40) 1.09 (0.95–1.24) 1.05 (0.90–1.22) 1.14 (0.90–1.46) 0.91 (0.68–1.22) 1.08 (0.84–1.40) 1.08 (0.99–1.18)
rs9277554 0.08 0.42 0.20 0.99 0.08 0.18 0.93
chr6:33163516
HLA-DPB1
0.91 (0.81–1.01) 0.96 (0.87–1.06) 1.07 (0.96–1.19) 1.00 (0.84–1.19) 1.19 (0.98–1.44) 1.13 (0.94–1.36) 1.00 (0.94–1.06)
rs441890 0.91 0.14 0.74 0.47 0.63 0.95 0.37
chr8:71727221
LACTB2
1.01 (0.90–1.13) 1.07 (0.98–1.17) 1.02 (0.92–1.12) 1.06 (0.90–1.25) 0.96 (0.80–1.15) 0.99 (0.84–1.18) 1.03 (0.97–1.09)
rs716183 0.84 0.78 0.35 0.59 0.94 0.80 0.49
chr10:118894485
VAX1
0.99 (0.88–1.10) 0.99 (0.90–1.08) 0.95 (0.87–1.05) 1.05 (0.89–1.23) 1.01 (0.84–1.20) 0.98 (0.83–1.16) 0.98 (0.93–1.04)
*Excluding SCALE1 for FL.
OR: odds ratio, CI: confidence interval.
doi:10.1371/journal.pgen.1001378.t003
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of NHL, in particular with DLBCL but also with FL [22], our
finding may suggest a molecular link between these diseases,
although their associations within this region of high LD could also
be due to different causal variants.
Previously, large-scale candidate gene studies have pointed to
susceptibility loci in the HLA class III region mainly between the
TNF variant –308G-.A (rs1800629) and risk of DLBCL [23,24].
We provide novel evidence of association of DLBCL with an
independent HLA marker in the class II region (rs10484561;
r
2=0), 1.1Mb away from rs1800629, strongly suggesting that
alleles in the HLA class II region may play an important role in the
pathogenesis of this subtype as well. The weaker association of
rs10484561 with DLBCL (OR 1.36) than with FL (OR 1.95) [6]
could imply that the DLBCL-association is confined to a subset of
DLBCL tumors with specific morphological or molecular features
more closely related to FL, such as the germinal center-like B-cell
phenotype [25]. However, the observed effects could also be due
to modification of other concurrent DLBCL-specific susceptibility
variants, or rs10484561 could tag a more strongly associated
marker in this region of high LD.
Moreover, we found suggestive evidence of association at
rs6536942 on 4q32.3, located within an intron of the tolloid-like 1
(TLL1) gene, with FL risk. However, larger studies are needed to
validate this finding. Although the strongest associations so far
have been observed in the HLA region, and extended pooling of
available scan data failed to identify additional loci outside of
HLA, we expect that future larger meta-GWAS efforts will more
robustly identify additional loci in other regions.
In conclusion, our results strongly suggest that future genetic
and functional work focused on the HLA class II region will
provide important insight into the disease pathology of FL,
DLBCL and other subtypes of NHL. In addition, further studies of
this region and potential interaction with environmental factors in
NHL risk, and of NHL prognosis are warranted.
Methods
Ethics statement
The studies described in this manuscript have been approved by
the ethics committee of the respective institutions: Karolinska
Institutet (Sweden), Scientific Ethics Committee system (Den-
mark), University of California, Berkeley (US), National Cancer
Institute, National Institutes of Health (US), Mayo Clinic (US),
University of British Columbia (Canada), Yale University (US),
University of Sydney (Australia).
Study subjects
The SCALE study is a population-based study of the etiology of
NHL carried out in all of Denmark and Sweden during 1999 to
2002 [26]. NHL subtype diagnoses were reviewed and reclassified
according to the World Health Organization (WHO) classification
[1] as previously described [26]. For this GWAS (SCALE1) we
used DNA from 400 cases with follicular lymphoma (FL; 150 from
Denmark and 250 from Sweden) and from 150 Danish controls,
individually matched to the Danish FL cases by sex and age at
study inclusion. We also used material collected from 673 control
subjects in a separate Swedish population-based case-control study
of rheumatoid arthritis (the Eira study) [21,27]. The latter was
conducted during 1996 to 2005 among residents 18 to 70 years of
age in the southern and central parts of Sweden (including 90% of
Swedish residents). Hence, the population controls recruited in this
study were considered to represent the same study population as
the Swedish component of the SCALE study with regard to
genetic variation. Genotyping completion rates were similar
between cases and controls; out of 400 cases and 823 controls
genotyped, 379 cases (95%) and 791 controls (96%) were included
in the final analysis. Study subjects used in Stages 2, 3 and
validation in other NHL subtypes (Table 1, Table S1, S2) have
been previously described [6,8–12], and details are available as
supporting text (Text S1). For the SCALE2 NHL subtype
validation study, we used the rest of the lymphoma cases with
blood samples originally recruited in SCALE (n=1869), Danish
control subjects not included in the GWAS (n=556), a second set
of control subjects from the Eira study (n=742) and a third group
of controls recruited in a national population-based case-control
study of breast cancer, the Cancer and Hormones Replacement in
Sweden (CAHRES) study [28] (n=720). The control subjects
from this study were randomly selected from the Swedish general
population to match the expected age distribution of the
participating breast cancer cases (50 to 74 years).
Genotyping
Stage I genotyping of 317,503 single nucleotide polymorphisms
(SNPs) was done on the HumanHap300 (version 1.0) array.
Validation genotyping was done using Sequenom iPlex; SNPs in
the human leukocyte antigen (HLA) region that failed primer
design for Sequenom assays were genotyped using Taqman
(Applied Biosystems).
Genome-wide association study
The scan included 317,503 SNPs from the HumanHap300
(version 1.0) array. The datasets were filtered on the basis of SNP
genotyping call rates ($.95% completeness), sample completion
rate ($90%), minor allele frequency (MAF; all subjects as well as
cases and controls separately $0.03) and non-deviation from
Hardy-Weinberg equilibrium (HWE; p,10
26). We also excluded
SNPs with cluster plot problems, and those on the X and Y
chromosomes. Study subjects with gender discrepancies and/or
labelling errors were removed. We also removed individual samples
with evidence of cryptic family relationships (identified using the–
genome command in PLINK). To detect outliers in terms of
population stratification, we performed principal component (PC)
analysis using the EIGENSTRAT software (Figure S4). A subset of
linkage disequilibrium (LD) thinned SNPs was selected such that all
pair-wise associations had r
2,0.2, and long-range regions of high
LD, reported to potentially confound genome scans, were removed
[29]. Twenty-five samples were removed as population outliers on
the basis of their values on the first three PCs. To adjust for possible
stratification in our association analyses we adjusted the regression
analyses using the first three PCs; the number of PCs used for
adjustment was determined by plotting the eigenvalues and locating
the position of the ‘‘elbow’’ on the scree plot (Figure S5). Wald tests,
treating minor allele counts as continuous covariates were used to
test for association. The genomic inflation factor (l) was calculated
to be 1.0283 after adjusting for the first three PCs, suggesting the
presence of minimal stratification. Quantile-quantile plots for the
associations before and after adjustment are shown in Figure S6.
Finally, we assessed associations of age and sex with main genotypes
among the control subjects to address the possibility of confounding
by these factors (Table S11). As there was no evidence of
associations of age or sex with genotypes among the controls, we
did not adjust for them in the final main effects analyses of
genotypes.
Validation and meta-analysis
In Stage 2, similar quality control measures were applied as in
Stage 1, including genotyping call rate $95%, sample completion
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association using trend tests. For meta-analyses across studies and
NHL subtypes, we used the Cochran-Mantel-Haenszel method to
calculate the combined odds ratio and P-value, and x
2 tests for
heterogeneity. Multivariate logistic regression was used to test for
independence of SNP effects. For validation among other NHL
subtypes, the control subjects were the same as those in Stages 2
and 3 for validation in FL for all studies except SCALE2. Only
European-ancestry subjects were included, and the possibility of
population stratification affecting the results has been thoroughly
explored and found to be low in earlier investigations in the same
populations [6,8].
Imputation
We used IMPUTEv1 for the imputation of SNPs from the 1000
Genomes pilot1 CEU data (August 2009 release); and the
HapMap Phase II release 22 CEU data. We set a strict threshold
for imputation, using only SNPs with confidence scores of $0.9,
call rates $90%, non-deviation from Hardy-Weinberg equilibri-
um P .0.001 and MAF .0.01. The imputation was done on the
Stage 1 samples separately for each of the two reference datasets
and SNPs showing a discordance of .5% between the genotypes
imputed with the two datasets were excluded from further analysis.
The data were then merged using HapMap II as the master
dataset to which additional imputed SNPs from the 1000
Genomes dataset were added. HLA alleles were imputed by
identifying tag SNPs [15] from the genotyped and imputed SNP
dataset. We used PLINK for haplotype imputation with the tag
SNPs and downstream association analyses. Only haplotypes with
call rates .90%, MAF.1% and probability thresholds .0.8 were
analyzed.
Haplotype and coalescence analyses
For coalescence analysis all 12 SNPs (genotyped in this study
and within a region of ,177 Kb) adjacent to the two SNPs
associated with the FL risk were used to construct haplotypes.
These were phased using the PHASE program [30] and tested for
association using PLINK. The ancestral haplotype was construct-
ed from the chimpanzee (PanTro2) allele whenever possible, and
otherwise from the macaque alleles. An ancestral recombination
graph was constructed using the program Beagle [13,31] which
allows recombination assuming an infinite site mutation model.
After identifying the first recombination event the haplotype
segment before the recombination spot was used to construct a
median –joining network using the Network program [14]. The
alleles of the imputed SNP rs9378212 were then phased on each
haplotype segment using the PHASE program.
The URLs for the data and analytic approaches presented
herein are as follows:
1000 Genomes http://1000genomes.org
HapMapII http://www.hapmap.org
IMPUTEv1 https://mathgen.stats.ox.ac.uk/impute/impute_v1.
html
mRNA by SNP browser http://www.sph.umich.edu/csg/
liang/asthma/
R script for recombination plot http://www.broadinstitute.org/
science/projects/diabetes-genetics-initiative/plotting-genome-wide-
association-results
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lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
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Figure S2 Association results for imputed SNPs and genotyped
SNPs.
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Table S3 Top 40 SNPs taken forward to Stage 2, sorted by
significance level (trend P-value) of association with risk of
follicular lymphoma.
Found at: doi:10.1371/journal.pgen.1001378.s009 (0.02 MB PDF)
Table S4 SNPs on chromosome 6p21.32 that showed genome-
wide per allele P-values , 1E-04 in association with risk of
follicular lymphoma in Stage 1, sorted by position.
Found at: doi:10.1371/journal.pgen.1001378.s010 (0.01 MB PDF)
Table S5 Summary statistics for associations with risk of
follicular lymphoma in Stages 1 and 2 with combined
P-values.
Found at: doi:10.1371/journal.pgen.1001378.s011 (0.02 MB PDF)
Table S6 Crude and adjusted logistic regression analyses of the
six SNPs in 6p21.32 showing significant association with risk of
follicular lymphoma in Stages 1 and 2.
Found at: doi:10.1371/journal.pgen.1001378.s012 (0.01 MB PDF)
Table S7 Individual study results for associations between the 5
SNPs taken forward to Stage 3 and risk of follicular lymphoma in
Stage 3.
Found at: doi:10.1371/journal.pgen.1001378.s013 (0.01 MB PDF)
Table S8 Genotype counts of main SNPs per Cases/Controls,
per study and in total.
Found at: doi:10.1371/journal.pgen.1001378.s014 (0.01 MB PDF)
Table S9 Associations with risk of follicular lymphoma for
haplotypes phased with 14 SNPs or 7 SNPs based on genotyped
SNPs in Stage 1.
Found at: doi:10.1371/journal.pgen.1001378.s015 (0.01 MB PDF)
Table S10 Imputation of HLA class II alleles and risk of
follicular lymphoma.
Found at: doi:10.1371/journal.pgen.1001378.s016 (0.01 MB PDF)
Table S11 Trend p-value of associations of age and sex with
main genotypes among controls subjects per study.
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